Small-Molecule Calcium Modulators for Lower-Toxicity EV Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compounds used to induce calcium influx for enhancing extracellular vesicle (EV) release, such as ionomycin and A23187, are toxic for in vivo utilization, limiting their application in vaccine adjuvants and immunotherapy.
Innovation Solution
Identification of small molecule compounds, such as ethyl 2-(benzo[c][1,2,5]thiadiazole-4-sulfonamido)-4,5-dimethylthiophene-3-carboxylate (compound 634), which induce calcium influx and enhance EV release from antigen-presenting dendritic cells, thereby increasing immunostimulatory potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If calcium ionophores (ionomycin, A23187) are used to enhance EV release, then EV secretion is improved, but cellular toxicity increases
Solution Approach 1:
The invention changes the chemical parameters of calcium ionophores by modifying the core structure (e.g., replacing macrocyclic rings with linear or cyclic non-macrocyclic structures) and adjusting functional groups to reduce toxicity while maintaining calcium transport capability. This structural parameter modification allows the compound to achieve the same biological function with improved safety profile.
Solution Approach 2:
The invention creates simplified copy structures that mimic the essential function of natural calcium ionophores without copying their toxic macrocyclic framework. By designing linear or non-macrocyclic analogs with comparable calcium-binding motifs, the patent achieves the desired EV release enhancement while eliminating the harmful properties of the original compounds.
2Reliability
If existing calcium ionophores are used as vaccine adjuvants, then immune response is enhanced, but safety for in vivo utilization deteriorates
Solution Approach 1:
The patent modifies key chemical parameters of calcium ionophores including molecular weight, structural rigidity, and functional group composition to reduce in vivo toxicity. These parameter changes maintain the compound's ability to induce calcium influx and enhance immune responses while improving safety for animal and human applications.
Solution Approach 2:
The invention introduces intermediate structural elements that mediate between the calcium-binding function and cellular compatibility. These intermediate structures (such as specific linker groups or modified ring systems) allow the compound to perform its immunostimulatory function while reducing direct toxic interactions with cellular components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The identified compounds effectively enhance EV release and costimulatory molecule expression, promoting antigen-specific T cell proliferation and vaccine immunogenicity, offering a safer and more effective adjuvant strategy.
Implementation Method 1
Intracellular Ca2+ influx is associated with both EV secretion and immune responses
Implementation Method 2
Recent reports indicate that the calcium ionophores ionomycin (ION) and A23187 enhance EV release
Data Source
AI summary
Provided herein are compounds that alter calcium mobilization and/or enhance extracellular vesicle production, compositions having the compounds, and methods of making and using the compounds.